2-ethyl-6-(3-piperidin-1-ylpropoxy)-3,4-dihydro-1H-isoquinoline;dihydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-ethyl-6-(3-piperidin-1-ylpropoxy)-3,4-dihydro-1H-isoquinoline;dihydrochloride
• 化学式: C19H32Cl2N2O
• 分子量: 375.4
• InChiKey: JQGIJJQGGVMFCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.16
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  15.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
  申请人：——

  公开号：US20040110748A1

  公开（公告）日：2004-06-10

  The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases. 1

  本发明公开了新型取代芳基烷基胺化合物的化学式（I）或其医药上可接受的盐，它们具有选择性的组胺H3受体拮抗活性，以及制备这些化合物的方法。在另一种实施方式中，本发明公开了包含这些环状胺的药物组合物，以及使用它们治疗肥胖症和其他组胺H3受体相关疾病的方法。
• NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
  申请人：Eli Lilly and Company

  公开号：EP1379493A2

  公开（公告）日：2004-01-14
• US7314937B2
  申请人：——

  公开号：US7314937B2

  公开（公告）日：2008-01-01
• [EN] NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] COMPOSES D'ARYL ALKYLAMINES NON IMIDAZOLE COMME ANTAGONISTES DES RECEPTEURS H3 DE L'HISTAMINE, PREPARATION ET APPLICATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2002076925A2

  公开（公告）日：2002-10-03

  The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereofwhich have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such cyclic amines as well as methods of using them to treat obesity and other histamine H3 receptor -related diseases.